Scientists discover how brain regulates fat metabolism

Scientists have discovered the brain region which controls whether excess energy should be stored as fat or burned in our muscles. The researchers hope that their findings will lead to the development of new treatments for obesity. The work, which was partly funded by the EU, is published in the Journal of Clinical Investigation.

The brain region in question is the melanocortin system. It is already known that this system receives messages from the gut indicating whether it is hungry or full. The system responds by causing the body to either take in or burn calories.

This latest piece of research reveals that the melanocortin system is also responsible for controlling whether extra energy should be converted to fat and whether it should be stored or metabolised.

Experiments in rats showed that when the system is stimulated to increase activity, fat is metabolised. When activity levels in the system are reduced, fat accumulation increases. All of this happens independently of levels of food intake.

"We were able, in essence, to change traffic signals in so-called nutrient highways in the body so that calories were metabolised, and not dumped into fat cells, and we did this without changing the rate of food intake," explains Matthias Tschöp, Associate Professor of Psychiatry at the University of Cincinnati, who led the research.

The team also studied people who suffer from obesity caused by a genetic defect in the melanocortin system. The results indicated that the problem was caused by a fault in the fat storage/burning mechanism.

"Our results do not just explain why reduced levels of melanocortin can lead to overweight, even without increased food intake, but they indicate new targets for the development of effective medicines for controlling overweight," said Professor Tschöp. "These are urgently needed if we are to overcome the problem of obesity which is growing around the world."

EU funding for the work came from the Sixth Framework Programme DIABESITY project, which is looking for novel molecular targets for obesity and type 2 diabetes. Earlier this year, researchers from the project identified a molecule which contributes to obesity by providing the link between spontaneous physical activity, such as fidgeting whilst working at a computer, and food intake.

For further information, please visit www.jci.org

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...